SAFETY, PHARMACOKINETIC, BIOMARKER, HISTOLOGIC, AND RECTAL BLEEDING ACTIVITY FOLLOWING TREATMENT WITH THE GUT-TARGETED, PHD-INHIBITOR AND HIF-1α STABILIZER GB004 IN A PHASE 1B TRIAL IN MILD-TO-MODERATE ULCERATIVE COLITIS

William Sandborn  1     Brian G. Feagan  2     Silvio Danese  3     Alina Jucov  4     B.R. Bhandari  5     Kartik Raghupathi  6     Allan Olson  6     Courtney Van Biene  7     Gregory J. Opiteck     Julia Ford     Richard Aranda     Barrett G. Levesque    
1 UC San Diego Health System,San Diego,United States
2 Robarts Clinical Trials Inc.,London,Canada
3 Humanitas Research Hospital,Rozzano,Italy
4 ARENSIA Exploratory Medicine GmbH,Dusseldorf,Germany
5 Delta Research Partners,Bastrop,United States
6 Gossamer Bio, Inc.,San Diego,United States
7 Gossam

Session
IBD Clinical II

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing